Monday, May 22, 2017

Immuno-Oncology Market Updates: In Melanoma, Incyte/BMS Significantly Out-Performed Merck/Incyte...

While we were incommunicado, this story broke -- at the annual US cancer meetings. Do go read all the abstracts, if you intend to trade on any of this news, though -- to be sure.

From the Friday edition of the Investor's Business Daily, then -- a bit:

. . . .Incyte stock enjoyed a fifth consecutive day of gains Friday after its immuno-oncology drug, epacadostat, proved robust in combination trials with Dow component Merck and Bristol-Myers Squibb. . . .

Between the two, Merck's Keytruda and Bristol-Myers' Opdivo were tested in combination with Incyte's epacadostat in eight forms of cancer. Among those, Bristol-Myers' matchup in melanoma grabbed the best response and disease control rates.

At the 100-milligram dose, melanoma patients treated with the Opdivo and epacadostat combination saw a 75% response rate and a 100% disease control rate, according to Janney analyst Debjit Chattopadhyay. . . .

Now you know. Onward, on another (non-life-sciences) unexpected, and fast-breaking, divestiture deal, now. . . . thus, back in the saddle a little earlier than expected. Grin.


No comments: